Advantage Energy (TSE:AAV – Free Report) (NYSE:AAV) had its price target lifted by Desjardins from C$13.00 to C$13.50 in a research note issued to investors on Monday morning, BayStreet.CA reports. They currently have a buy rating on the stock. Other equities research analysts also recently issued research reports about the stock. Royal Bank of Canada […]
Advantage Energy (TSE:AAV – Get Free Report) (NYSE:AAV) had its price objective upped by Desjardins from C$13.00 to C$13.50 in a note issued to investors on Monday, BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Desjardins’ price objective indicates a potential upside of 24.31% from the company’s current price. Several other […]
Advantage Energy (TSE:AAV – Get Free Report) (NYSE:AAV) had its price target upped by analysts at Desjardins from C$13.00 to C$13.50 in a research report issued on Monday, BayStreet.CA reports. The firm presently has a “buy” rating on the stock. Desjardins’ price objective points to a potential upside of 24.31% from the company’s previous close. […]
Pfizer Inc.’s Beqvez (fidanacogene elaparvovec) won FDA approval for use in adults with hemophilia B, making it the second adeno-associated viral (AAV) vector-based gene therapy available for patients in the U.S., following the late 2022 approval of CSL Behring’s Hemgenix (etranacogene dezaparvovec).
TD Securities restated their buy rating on shares of Advantage Energy (TSE:AAV – Free Report) (NYSE:AAV) in a report issued on Friday, Stock Target Advisor reports. The firm currently has a C$14.00 price target on the stock. Several other research analysts have also recently issued reports on the company. National Bankshares upped their price objective […]